Validation of the Italian translation of the Inflammatory Bowel Disease Questionnaire

Digestive and Liver Disease

Volumn 43, Issue 7, 2011, Pages 535-541

  Ciccocioppo, Rachele ^a   Klersy, Catherine ^a   Russo, Maria Luisa ^a   Valli, Monica ^a   Boccaccio, Vincenzo ^a   Imbesi, Venerina ^a   Ardizzone, Sandro ^b   Porro, Gabriele Bianchi ^b   Corazza, Gino Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Inflammatory bowel disease; Quality of life; Questionnaire; Validation

Indexed keywords

ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; CROHN DISEASE; CRONBACH ALPHA COEFFICIENT; DISCRIMINANT VALIDITY; DISEASE ACTIVITY; FACTORIAL ANALYSIS; FEMALE; GENDER; HUMAN; INTERNAL CONSISTENCY; ITALY; MAJOR CLINICAL STUDY; MALE; MCMASTER INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL; QUALITY OF LIFE; QUESTIONNAIRE; SHORT FORM 36; TEST RETEST RELIABILITY; ULCERATIVE COLITIS;

ADULT; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; ITALY; LANGUAGE; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; TRANSLATING;

EID: 79957616396     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2010.12.014     Document Type: Article

References (61)

1. Baumgart D.C., Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007, 369:1641-1657.
2. Geboes K., Rutgeerts P., Opdenakker G., et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin 2005, 21:1741-1754.
3. Gies N., Kroeker K.I., Wong K., et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single center cohort. Aliment Pharmacol Ther 2010, 32:522-528.
4. Bernstein C.N., Fried M., Krabshuis J.H., et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010, 16:112-124.
5. Rogala L., Miller N., Graff L.A., et al. Population-based controlled study of social support, self-perceived stress, activity and work issue, and access to health care in Inflammatory Bowel Disease. Inflamm Bowel Dis 2008, 14:526-535.
6. Casellas F., López-Vivancos J., Casado A., et al. Factors affecting health related quality of life of patients with inflammatory bowel disease. Qual Life Res 2002, 11:775-781.
7. Bernklev T., Jahnsen J., Schulz T., et al. Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. Eur J Gastroenterol Hepatol 2005, 17:1037-1045.
8. Bernklev T., Jahnsen J., Henriksen M., et al. Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2006, 12:402-412.
9. Sandborn W.J., Feagan B.G., Hanauer S.B., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002, 122:512-530.
10. D'Haens G., Sandborn W.J., Feagan B.G., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132:763-786.
11. Irvine E.J. Quality of Life-rationale and methods for developing a disease-specific instrument for inflammatory bowel disease. Scand J Gastroenterol Suppl 1993, 199:22-27.
12. Irvine E.J., Feagan B., Rochon J., et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994, 106:287-296.
13. Casellas F., López-Vivancos J., Badia X., et al. Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol 2001, 13:567-572.
14. Reilly M.C., Gerlier L., Brabant Y., et al. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Clin Ther 2008, 30:393-404.
15. Guyatt G., Mitchell A., Irvine E.J., et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989, 96:804-810.
16. Hoivik M.L., Bernklev T., Moum B. Need for standardization in population-based quality of life studies: a review of the current literature. Inflamm Bowel Dis 2010, 16:525-536.
17. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
18. Apolone G., Mosconi P. The Italian SF-36 Health Survey: translation, validation and norming. J Clin Epidemiol 1998, 51:1025-1036.
19. Bullinger M., Alonso J., Apolone G., et al. Translating health status questionnaires and evaluating their quality: the IQOLA project approach. International quality of life assessment. J Clin Epidemiol 1998, 51:913-923.
20. Gausche C., Scholmerich J., Brynskov J., et al. A simple classification of Crohn's disease: report of the working party for the World Congresses of Gastroenterology. Vienna 1998. Inflamm Bowel Dis 2000, 6:8-15.
21. Best W.R., Becktel J.M., Singleton J.W., et al. Development of a Crohn's disease activity index, National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70:439-444.
22. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J 1989, 298:82-86.
23. Mary J.Y., Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1998, 30:983-989.
24. Ware J.E., Gandek B. Methods for testing data quality, scaling assumptions, and reliability: the IQOLA project approach. International quality of life assessment. J Clin Epidemiol 1998, 51:945-952.
25. de Boer A.G., Wijker W., Bartelsman J.F., et al. Inflammatory Bowel Disease Questionnaire: cross-cultural adaptation and further validation. Eur J Gastroenterol Hepatol 1995, 7:1043-1050.
26. Han S.W., McColl E., Steen N., et al. The inflammatory bowel disease questionnaire: a valid and reliable measure in ulcerative colitis patients in the North East of England. Scand J Gastroenterol 1998, 33:961-966.
27. López-Vivancos J., Casellas F., Badia X., et al. Validation of the Spanish version of the inflammatory bowel disease questionnaire on ulcerative colitis and Crohn's disease. Digestion 1999, 60:274-280.
28. Cheung W.Y., Garratt A.M., Russell I.T., et al. The UK IBDQ-A British version of the inflammatory bowel disease questionnaire. Development and validation. J Clin Epidemiol 2000, 53:297-306.
29. Hjortswang H., Järnerot G., Curman B., et al. Validation of the inflammatory bowel disease questionnaire in Swedish patients with ulcerative colitis. Scand J Gastroenterol 2001, 36:77-85.
30. Bernklev T., Moum B., Moum T. Inflammatory Bowel South-Eastern Norway (IBSEN) Group of Gastroenterologists. Quality of life in patients with inflammatory bowel disease: translation, data quality, scaling assumptions, validity, reliability and sensitivity to change of the Norwegian version of IBDQ. Scand J Gastroenterol 2002, 37:1164-1174.
31. Vlachonikolis I.G., Pallis A.G., Mouzas I.A. Improved validation of the Inflammatory Bowel Disease Questionnaire and development of a short form in Greek patients. Am J Gastroenterol 2003, 98:1802-1812.
32. Hashimoto H., Green J., Iwao Y., et al. Reliability, validity, and responsiveness of the Japanese version of the Inflammatory Bowel Disease Questionnaire. J Gastroenterol 2003, 38:1138-1143.
33. Stjernman H., Grännö C., Bodemar G., et al. Evaluation of the Inflammatory Bowel Disease Questionnaire in Swedish patients with Crohn's disease. Scand J Gastroenterol 2006, 41:934-943.
34. Ren W.H., Lai M., Chen, et al. Validation of the Mainland Chinese Version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for Ulcerative Colitis and Crohn's Disease. Inflamm Bowel Dis 2007, 13:903-910.
35. Verissimo R. Quality of life in inflammatory bowel disease: psychometric evaluation of an IBDQ cross-culturally adapted version. J Gastrointest Liver Dis 2008, 17:439-444.
36. Irvine E.J. Quality of Life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis 2008, 14:554-565.
37. Clearfield H.R. How does IBD affect quality of life?. Inflamm Bowel Dis 2008, 14:S45-S46.
38. Sostegni R., Daperno M., Scaglione N., et al. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 2003, 17(Suppl. 2):11-17.
39. Irvine E.J., Greenberg G.R., Feagan B.G., et al. Quality of life rapidly improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. Inflamm Bowel Dis 2000, 6:181-187.
40. Casellas F., López-Vivancos J., Badia X., et al. Impact of surgery for Crohn's disease on health-related quality of life. Am J Gastroenterol 2000, 95:177-182.
41. Lichtenstein G.R., Bala M., Han C., et al. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002, 8:237-243.
42. Feagan B.G., Yan S., Bala M., et al. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003, 98:2232-2238.
43. Casellas F., Rodrigo L., Niño P., et al. Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years. Inflamm Bowel Dis 2007, 13:1395-1400.
44. Feagan B.G., Sandborn W.J., Hass S., et al. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroenterol 2007, 102:2737-2746.
45. Feagan B.G., Reinisch W., Rutgeerts P., et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007, 102:794-802.
46. Loftus E.V., Feagan B.G., Colombel J.F., et al. Effects of adalimumab maintenance therapy on Health-Related Quality of Life of patients with Crohn's disease: patient-reported outcomes of the CHARM Trial. Am J Gastroenterol 2008, 103:3132-3141.
47. Irvine E.J., Yeh C.H., Ramsey D., et al. The effect of mesalamine therapy on quality of life in patients with mildly to moderately active ulcerative colitis. Aliment Pharmacol Ther 2008, 28:1278-1286.
48. Rutgeerts P., Schreiber S., Feagan B., et al. CDP870 Crohn's Disease Study Group. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis 2008, 23:289-296.
49. Bastida G., Nos P., Aguas M., et al. The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients. BMC Gastroenterol 2010, 10:26.
50. Dotan I., Rachmilewitz D., Schreiber S., et al. A randomized placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Gut 2010, 59:760-766.
51. Irvine E.J. Quality of Life in inflammatory bowel disease: biases and other factors affecting scores. Scand J Gastroenterol 1995, 208(Suppl.):136-140.
52. McColl E., Han S.W., Barton J.R., et al. A comparison of the discriminatory power of the Inflammatory Bowel Disease Questionnaire and the SF-36 in people with ulcerative colitis. Qual Life Res 2004, 13:805-811.
53. Haapamäki J., Roine R.P., Sintonen H., et al. Health-related quality of life in inflammatory bowel disease measured with the generic 15D instrument. Qual Life Res 2010, 19:919-928.
54. Zahn A., Hinz U., Karner M., et al. Health-related quality of life correlates with clinical and endoscopic activity indexes but not with demographic features in patients with ulcerative colitis. Inflamm Bowel Dis 2006, 12:1058-1067.
55. Hlavaty T., Persoons P., Vermeire S., et al. Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's disease. Inflamm Bowel Dis 2006, 12:199-204.
56. Casellas F., Vivancos J.L., Sampedro M., et al. Relevance of the phenotypic characteristics of Crohn's disease in patient perception of health-related quality of life. Am J Gastroenterol 2005, 100:2737-2742.
57. Kiebles J.L., Doerfler B., Keefer L. Preliminary evidence supporting a framework of psychological adjustment to inflammatory bowel disease. Inflamm Bowel Dis 2010, 16:1685-1695.
58. Dorrian A., Dempster M., Adair P. Adjustment to inflammatory bowel disease: the relative influence of illness perceptions and coping. Inflamm Bowel Dis 2009, 15:47-55.
59. Hjortswang H., Järnerot G., Curman B., et al. The influence of demographic and disease-related factors on health-related quality of life in patients with ulcerative colitis. Eur J Gastroenterol Hepatol 2003, 15:1011-1020.
60. Haapamäki, Turunen U., Roine R.P., et al. Impact of demographic factors, medication and symptoms on disease-specific quality of life in inflammatory bowel disease. Qual Life Res 2009, 18:961-969.
61. Pallis A.G., Mouzas I.A., Vlachonikolis I.G. The inflammatory bowel disease questionnaire: a review of its national validation studies. Inflamm Bowel Dis 2004, 10:261-269.